Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc logo
FULC

Fulcrum Therapeutics Inc (FULC)

$12.872.39%

Market is closed
– opens on 8 PM, 30 Jan 2023
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$12.41
Day's Range
$12.87
$3.21
52-Week Range
$24.79
1 month return77.76%
3 month return131.47%
1 year return5.84%
5 year return4.67%

Analyst Recommendation

based on 15 analysts ratings

Buy
86%
Buy
13%
Hold
0%
Sell

Based on 15 Wall street analysts offering stock ratings for Fulcrum Therapeutics Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 75.29%

Current

$12.87

Target

$22.56

Recommendation Trend

Based on 15 analyst

Current1M Ago3M Ago
Buy
13
12
12
Hold
2
2
2
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization793.7M
Book Value$4.25
Dividend Share0.0
Dividend Yield0.0%
Earnings Per Share (EPS)-2.38
Wall Street Target Price22.56

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)1.28
Enterprise Value75.4M
Enterprise Value/Revenue7.04
Enterprise Value/Ebitda-0.72

Technicals

Beta1.9
50 Day MA8.37
200 Day MA7.65

Institutional Holdings

FMR Inc

15.0%

RA Capital Management, LLC

13.45%

RTW INVESTMENTS, LLC

7.66%

TRV GP III, LLC

7.61%

Suvretta Capital Management, LLC

6.78%

BlackRock Inc

5.33%

Company Information

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta thalassemia into Phase 1 clinical development.
OrganizationFulcrum Therapeutics Inc
Employees104
CEOMr. Bryan E. Stuart
IndustryHealth Technology

Discover more

Frequently Asked Questions

What is Fulcrum Therapeutics Inc share price today?

Can Indians buy Fulcrum Therapeutics Inc shares?

How can I buy Fulcrum Therapeutics Inc shares from India?

Can Fractional shares of Fulcrum Therapeutics Inc be purchased?

What are the documents required to start investing in Fulcrum Therapeutics Inc stocks?

What are today’s High and Low prices of Fulcrum Therapeutics Inc?

What are today’s traded volumes of Fulcrum Therapeutics Inc?

What is today’s market capitalisation of Fulcrum Therapeutics Inc?

What is the 52 Week High and Low Range of Fulcrum Therapeutics Inc?

How much percentage Fulcrum Therapeutics Inc is down from its 52 Week High?

How much percentage Fulcrum Therapeutics Inc is up from its 52 Week low?

What are the historical returns of Fulcrum Therapeutics Inc?

Who is the Chief Executive Officer (CEO) of Fulcrum Therapeutics Inc?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*